Diabetes & GLP-1 medications in shortage

These diabetes and GLP-1 medications are currently on the FDA shortage list. Click one for its per-manufacturer, per-strength record and a change-only email alert. This is a curated list of diabetes medications; the FDA's own therapeutic category is Endocrinology/Metabolism.

Demand for GLP-1 medications has surged, and several diabetes drugs are listed by the FDA as in shortage or being discontinued. Note that the popular injectable GLP-1 brands Ozempic and Wegovy are not on the FDA shortage list — the GLP-1 drugs listed here are the oral semaglutide tablet (Rybelsus) and liraglutide (Victoza). The FDA's shortage list is the official national record of which manufacturers and strengths are affected; it is not your pharmacy's shelf. Always confirm with your pharmacist, and see what to do if your medication is in shortage.

Semaglutide Tablet also: Rybelsus Not specified 3 1 manufacturers, 3 FDA-listed presentations Liraglutide Injection also: Liraglutide, Saxenda, Victoza Limited 3Available 6Not specified 1 4 manufacturers, 10 FDA-listed presentations Insulin Lispro Injection also: Humalog Tempo Pen, Insulin Lispro Junior Kwikpen Not specified 2 1 manufacturers, 2 FDA-listed presentations Insulin Glargine Injection Not specified 1 1 manufacturers, 1 FDA-listed presentations Pramlintide Acetate Injection also: Symlinpen Not specified 2 1 manufacturers, 2 FDA-listed presentations

This is the FDA's national supply record, not your pharmacy's shelf. A manufacturer listed "Available" can still be out of stock locally; ask your pharmacist. See what to do if your medication is in shortage.

FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).